

heading of this document. The guidance document and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: July 5, 2002.

**Linda S. Kahan,**

*Deputy Director, Center for Devices and Radiological Health.*

[FR Doc. 02-17958 Filed 7-16-02; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Science and Regulation of Biological Products: From a Rich History to a Challenging Future; Public Symposium

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public symposium.

The Food and Drug Administration (FDA) is announcing a public symposium entitled "Science and Regulation of Biological Products: From a Rich History to a Challenging Future." The purpose of the symposium is to commemorate the 100th anniversary of the enactment of the Biologics Control Act, the first Federal law regulating biological products. The symposium is dedicated to the memory and achievements of Dr. Harry Meyer, Jr., who, together with Dr. Paul Parkman, developed the first licensed rubella virus vaccine. The Center for Biologics Evaluation and Research (CBER) staff and invited guests will present scientific lectures describing the achievements of the past and the challenges of the future in the areas regulated by CBER (blood, vaccines, and therapeutic biological products).

**Date and Time:** The public symposium will be held on Monday, September 23, 2002, from 8:30 a.m. to 5 p.m., and Tuesday, September 24, 2002, from 8:30 a.m. to 12 noon.

**Location:** The public symposium will be held at the National Institutes of Health (NIH), Natcher Conference Center, Bldg. 45, 45 Center Dr., Bethesda, MD.

**Contact:**

*For information about this notice:* Michael D. Anderson, Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-6210, FAX 301-594-1944.

*For information about the public symposium:* Gail Sherman, Center for Biologics Evaluation and Research

(HFM-42), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-2000, FAX 301-827-3079, e-mail: Sherman@cber.fda.gov.

**Registration:** Mail, fax, or e-mail your registration information (including name, professional degree, title, e-mail address, firm name, address, telephone, and fax number) to Gail Sherman by September 1, 2002. There is no registration fee for the public symposium. Space is limited, therefore, interested parties are encouraged to register early. There will be no onsite registration.

**Travel Information:** The NIH campus is accessible via the Washington, DC metro system, Red Line, at the Medical Center stop. The Natcher Conference Center is a short walk from the metro station, or you may take one of the many shuttle buses that run from the metro station to the various buildings on the campus. Due to newly imposed security measures, visitors parking is limited and use of private vehicles may cause significant delays in entering the campus.

If you need special accommodations due to a disability, please contact Gail Sherman at least 7 days in advance.

Dated: July 11, 2002.

**Margaret M. Dotzel,**

*Associate Commissioner for Policy.*

[FR Doc. 02-18039 Filed 7-16-02; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Advisory Commission of Childhood Vaccines; Request for Nominations for Voting Members

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Health Resources and Services Administration (HRSA) is requesting nominations to fill three vacancies on the Advisory Commission on Childhood Vaccines (ACCV). The ACCV was established by Title XXI of the Public Health Service Act (the Act), as enacted by Public Law (Pub. L.) 99-660 and as subsequently amended, and advises the Secretary of Health and Human Services (the Secretary) on issues related to implementation of the National Vaccine Injury Compensation Program (VICP).

**DATES:** The agency must receive nominations on or before August 16, 2002.

**ADDRESSES:** All nominations are to be submitted to the Director, Division of Vaccine Injury Compensation, Office of Special Programs, HRSA, Parklawn Building, Room 8A-46, 5600 Fishers Lane, Rockville, Maryland 20857.

**FOR FURTHER INFORMATION CONTACT:** Ms. Cheryl A. Lee, Principal Staff Liaison, Policy Analysis Branch, Division of Vaccine Injury Compensation, at (301) 443-2124.

**SUPPLEMENTARY INFORMATION:** Under the authorities that established the ACCV, viz. the Federal Advisory Committee Act of October 6, 1972 (Public Law 92-463) and section 2119 of the Act, 42 U.S.C. 300aa-19, as added by Public Law 99-660 and amended, HRSA is requesting nominations for three voting members of the ACCV.

The ACCV advises the Secretary on the implementation of the VICP. The activities of the ACCV include: Recommending changes in the Vaccine Injury Table at its own initiative or as the result of the filing of a petition; advising the Secretary in implementing section 2127 regarding the need for childhood vaccination products that result in fewer or no significant adverse reactions; surveying Federal, State, and local programs and activities related to gathering information on injuries associated with the administration of childhood vaccines, including the adverse reaction reporting requirements of section 2125(b); advising the Secretary on the methods of obtaining, compiling, publishing, and using credible data related to the frequency and severity of adverse reactions associated with childhood vaccines; and recommending to the Director of the National Vaccine Program that vaccine safety research be conducted on various vaccine injuries.

The ACCV consists of nine voting members appointed by the Secretary as follows: Three health professionals, who are not employees of the United States Government and have expertise in the health care of children, the epidemiology, etiology and prevention of childhood diseases, and the adverse reactions associated with vaccines, at least two shall be pediatricians; three members from the general public, at least two shall be legal representatives (parents or guardians) of children who have suffered a vaccine-related injury or death; and three attorneys, at least one shall be an attorney whose specialty includes representation of persons who have suffered a vaccine-related injury or death, and one shall be an attorney